International Stem Cell Corp. continues its pursuit of
advancing regenerative medicine through its use and research of stem cells in
the white hot biotechnology space. ISCO uses parthenogenesis, a stem cell
technology that makes use of unfertilized eggs to address immune system
rejection. The eggs being used have mirroring sets of human leukocyte antigen
genes (HLA) that reduce the chance of immune system rejection. Not to be
overlooked, it’s worth noting that one line of these cells can treat multiple
millions of people. The company can draw human parthenogenetic neural stem
cells (hpNSC) from the unfertilized eggs for self-renewing processes that are
integral to the degeneration process.
Following continuous successful testing, International Stem
Cell Corp. suggests that their human parthenogenetic neural stem cells can take
the place of dead and dying neurons while also protecting existing ones when
transplanted into the brain of someone with Parkinson’s disease. Further,
company researchers and scientists are progressing toward developing human
retinal epithelium (RPE) cells that are used in the treatment of eye diseases
like age-related macular degeneration. Along with that research, the company is
one of the world’s select few to develop a method for creating corneal tissue
and cells to treat blindness.
International Stem Cell has recently announced its
development of technology that creates functional cartilage from a person’s
skin to treat a joint disease that erodes cartilage infamously known as
osteoarthritis. The company is also making strides aside from therapeutic
systems that, according to Chief Scientific Officer, Ruslan Semechkin, PhD,
“can potentially be treated with the patient’s own cells.”
Running concurrent with its work in the area of regenerative
techniques, International Stem Cell Corp. runs a cosmeceutical line called
Lifeline Skin Care Inc. This business makes cosmetic skin care products all
over the globe. The company’s research and development in this area uses
parthenogenetic stem cells, vitamins and minerals to create a rejuvenating
serum leading to healthier skin.
International Stem Cell Corp. works on therapeutic applications
of human parthenogenetic stem cells and the development and commercialization
of cell-based research and cosmetic products. The company’s primary technology
of parthenogenesis nets the creation of pluripotent human stem cells from
unfertilized oocytes. Company scientists have created the first
parthenogenetic, homozygous stem cell line that is considered by many to be a
source of therapeutic cells for hundreds of millions of individuals of
differing genders, racial background and ages.
For more information about the company, visit
www.internationalstemcell.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment